1. European Medicines Agency. Guideline on good pharmacovigilance practices (GVP): Annex I - Definitions (Rev 4); 9 Oct 2017. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-annex-i-definitions-rev-4_en.pdf
2. Centers for Disease Control and Prevention. CDC coronavirus disease 2019 (COVID-19): people with certain medical conditions. https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html. Accessed 14 Sep 2020.
3. Centers for Disease Control and Prevention. CDC COVID data tracker. https://covid.cdc.gov/covid-data-tracker/. Accessed 26 Oct 2020.
4. Walz L, Cohen AJ, Rebaza AP, Vanchieri J, Slade MD, Cruz CSD, et al. JAK-inhibitor and type I interferon ability to produce favorable clinical outcomes in COVID-19 patients: a systematic review and meta-analysis. Res Sq. 2020:rs.3.rs-64782.
5. Hsu JJ, Gaynor P, Kamath M, Fan A, Al-Saffar F, Cruz D, et al. COVID-19 in a high-risk dual heart and kidney transplant recipient. Am J Transplant. 2020;20:1911–5.